<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03120247</url>
  </required_header>
  <id_info>
    <org_study_id>IORG0006563/no. 377</org_study_id>
    <nct_id>NCT03120247</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of Oral Transmucosal Dexmedetomidine.</brief_title>
  <acronym>OTM/DEX/PK</acronym>
  <official_title>Pharmacokinetics and Pharmacodynamics of Three Doses of Oral Trans-mucosal Dexmedetomidine for Premedication in Patients Undergoing Modified Radical Mastectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral trans-mucosal administration is relatively easy and convenient, it also reduces first
      pass metabolism and has been used successfully for fentanyl, ketamine, and midazolam
      premedication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The alpha2-adrenoceptor agonist, dexmedetomidine, was originally developed as a sedative and
      analgesic drug for use in intensive care. However, it has a number of unique pharmacodynamic
      properties, which also make it useful in anesthesia including; decreased MAC, analgesia
      without respiratory depression and a significant reduction in catecholamine secretion. Also
      it has been used off-label as an adjunctive agent for sedation and analgesia in patients in
      the critical care unit and for sedation during non-invasive procedures in radiology. It also
      has a potential role as part of anesthesia care to prevent emergence delirium and
      post-anesthesia shivering.

      Oral trans-mucosal administration is relatively easy and convenient, it also reduces first
      pass metabolism and has been used successfully for fentanyl, ketamine, and midazolam
      premedication.

      The current literature is focused in studying the sedative and analgesic effects of
      intravenously administered dexmedetomidine. Pharmacodynamics and pharmacokinetic studies
      undertaken on alternative routes of dexmedetomidine administration are lacking. The
      pharmacokinetic properties of trans-mucosal administration of dexmedetomidine have been
      demonstrated in one study only, and the clinical effects of non-parenteral administration of
      dexmedetomidine have been described in anecdotal case reports.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pharmacokinetic and pharmacodynamic study of three different doses of oral transmucosal dexmedetomidine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>360 minutes.</time_frame>
    <description>Two milliliters of blood will be collected for determination of Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation preoperative</measure>
    <time_frame>30 minutes</time_frame>
    <description>Sedation score is recorded pre-operatively every 5minutes for 30 minutes after OTM DEX administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure preoperative</measure>
    <time_frame>30 minutes.</time_frame>
    <description>Non invasive blood pressure will be recorded every 5 minutes for 30 minutes after OTM DEX administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate preoperative</measure>
    <time_frame>30 minutes</time_frame>
    <description>Heart rate will be recorded every 5 minutes for 30 minutes after OTM DEX administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>360 minutes.</time_frame>
    <description>Two milliliters of blood will be collected for determination of Area under the plasma concentration versus time</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>DEX I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OTM Dexmetetomidine 1µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEX II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OTM Dexmetetomidine0.75µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEX III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OTM Dexmetetomidine 0.5µg/kg. Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTM Dexmedetomidine 1µg/ kg.</intervention_name>
    <description>Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.</description>
    <arm_group_label>DEX I</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTM Dexmedetomidine 0.75µg/ kg.</intervention_name>
    <description>Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.</description>
    <arm_group_label>DEX II</arm_group_label>
    <other_name>Precedx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTM Dexmedetomidine 0.5µg/ kg.</intervention_name>
    <description>Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.</description>
    <arm_group_label>DEX III</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status I - II.

          -  Aged between 20 and 60 years.

          -  Scheduled for modified radical mastectomy

        Exclusion Criteria:

          -  Cardiac disease.

          -  Hepatic disease.

          -  Renal disease.

          -  History of alcohol or drug abuse.

          -  Patients with a known allergy to the study drug
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saher A Mohamed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant professor in anesthesia and pain management, South Egypt Cancer Institute, faculty of medicine, Assiut university.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hala S Abdel-Ghaffar, MD</last_name>
    <phone>+2 01003812011</phone>
    <email>hallasaad@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saher A Mohamed, MD</last_name>
    <phone>+2 01003611410</phone>
    <email>drsaher2008@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>South Egypt cancer institute, Assiut university</name>
      <address>
        <city>Asyut</city>
        <state>Assiut Governorate</state>
        <zip>715715</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hala S Abdel-Ghaffar, MD</last_name>
      <phone>+2 01003812011</phone>
      <email>hallasaad@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Saher A Mohamed, MD</last_name>
      <phone>+2 01003611410</phone>
      <email>drsaher2008@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2017</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hala Saad Abdel-Ghaffar</investigator_full_name>
    <investigator_title>Assistant professor in anesthesia and intensive care, Faculty of medicine, Assiut university, Egypt.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

